関節リウマチ（Rheumatoid Arthritis）治療薬の世界市場予測および分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 25
2 Introduction 28
2.1 Catalyst 28
2.2 Related Reports 29
2.3 Upcoming Related Reports 29
3 Disease Overview 30
3.1 Etiology and Pathophysiology 30
3.1.1 Etiology 30
3.1.2 Pathophysiology 30
3.2 Symptoms 35
3.3 Prognosis 36
3.4 Quality of Life 36
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities 37
4.3 Global Trends 39
4.3.1 US 39
4.3.2 5EU 40
4.3.3 Japan 41
4.3.4 Australia 41
4.3.5 China 42
4.3.6 India 42
4.4 Forecast Methodology 42
4.4.1 Sources Used 45
4.4.2 Sources Not Used 49
4.4.3 Forecast Assumptions and Methods – Total Prevalent Cases of RA 50
4.4.4 Forecast Assumptions and Methods – Diagnosed Prevalent Cases of RA 54
4.5 Epidemiological Forecast for RA (2013-2023) 55
4.5.1 Total Prevalent Cases of RA 55
4.5.2 Age-Specific Total Prevalent Cases of RA 57
4.5.3 Sex-Specific Total Prevalent Cases of RA 59
4.5.4 Diagnosed Prevalent Cases of RA 61
4.5.5 Age-Standardized Diagnosed Prevalence of RA 63
4.6 Discussion 65
4.6.1 Epidemiological Forecast Insight 65
4.6.2 Limitations of the Analysis 65
4.6.3 Strengths of the Analysis 66
5 Disease Management 67
5.1 Diagnosis and Treatment Overview 67
5.1.1 Diagnosis 67
5.1.2 Treatment Guidelines 69
5.1.3 Leading Prescribed Drugs for the Treatment of RA 78
5.1.4 Clinical Practice 79
5.2 US 84
5.3 France 88
5.4 Germany 89
5.5 Italy 92
5.6 Spain 94
5.7 UK 95
5.8 Japan 99
5.9 Australia 101
5.10 China 103
5.11 India 105
6 Competitive Assessment 108
6.1 Overview 108
6.2 Product Profiles – Major Brands 109
6.2.1 Enbrel (etanercept) 109
6.2.2 Humira (adalimumab) 116
6.2.3 Remicade (infliximab) 120
6.2.4 Simponi (golimumab) 126
6.2.5 Cimzia (certolizumab pegol) 132
6.2.6 Orencia (abatacept) 136
6.2.7 Actemra/RoActemra (tocilizumab) 142
6.2.8 Rituxan/MabThera (rituximab) 150
6.2.9 Inflectra/Remsima (infliximab biosimilar) 155
6.2.10 Xeljanz (tofacitinib) 158
6.2.11 Iguratimod/T-614 165
6.2.12 Methotrexate (Numerous Brands) 169
6.3 Biosimilars 172
6.3.1 Introduction 172
6.3.2 Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases 174
6.3.3 Biosimilars in the Immunology Community 174
6.3.4 By the Numbers: Biosimilars in Development 175
6.3.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 179
6.3.6 Uptake of Biosimilars for RA is Expected to Vary by Market 180
6.3.7 Biosimilars’ Forecast 183
6.4 Other Therapies 191
7 Unmet Need and Opportunity 193
7.1 Overview 193
7.2 Development of Cost-Effective Therapies 194
7.2.1 Unmet Need 194
7.2.2 Gap Analysis 195
7.2.3 Opportunity 195
7.3 Biomarkers to Predict Responsiveness to Therapy 196
7.3.1 Unmet Need 196
7.3.2 Gap Analysis 198
7.3.3 Opportunity 198
7.4 Early Diagnosis of RA 199
7.4.1 Unmet Need 199
7.4.2 Gap Analysis 200
7.4.3 Opportunity 201
7.5 Personalized Treatment Approach 202
7.5.1 Unmet Need 202
7.5.2 Gap Analysis 202
7.5.3 Opportunity 204
8 Pipeline Assessment 206
8.1 Overview 206
8.2 Clinical Trial Mapping 206
8.2.1 Clinical Trials by Class 206
8.3 Promising Drugs in Clinical Development 208
8.3.1 Sarilumab 215
8.3.2 Sirukumab 223
8.3.3 Clazakizumab 230
8.3.4 Cosentyx (secukinumab) 236
8.3.5 Tregalizumab 242
8.3.6 Mavrilimumab 248
8.3.7 Denosumab (Prolia/Xgeva) 253
8.3.8 Baricitinib 259
8.3.9 Peficitinib 269
8.3.10 Decernotinib 275
8.3.11 Filgotinib 281
8.3.12 Masitinib 287
8.3.13 RAVAX 294
8.4 Other Drugs in Development 299
9 Current and Future Players 302
9.1 Trends in Corporate Strategy 305
9.2 Company Profiles 306
9.2.1 AbbVie 306
9.2.2 Pfizer 308
9.2.3 Amgen 311
9.2.4 Johnson & Johnson 314
9.2.5 Eli Lilly 316
9.2.6 Bristol-Myers Squibb 318
9.2.7 UCB 320
9.2.8 Roche 321
9.2.9 GlaxoSmithKline 323
9.2.10 Novartis 325
9.2.11 Sanofi 327
9.2.12 AstraZeneca- MedImmune 329
9.2.13 Astellas 331
9.2.14 Vertex 333
9.2.15 Daiichi Sankyo 335
10 Market Outlook 338
10.1 Global Markets 338
10.1.1 Forecast 338
10.1.2 Drivers and Barriers – Global Issues 343
10.2 United States 345
10.2.1 Forecast 345
10.2.2 Key Events 351
10.2.3 Drivers and Barriers 352
10.3 France 354
10.3.1 Forecast 354
10.3.2 Key Events 359
10.3.3 Drivers and Barriers 359
10.4 Germany 362
10.4.1 Forecast 362
10.4.2 Key Events 367
10.4.3 Drivers and Barriers 368
10.5 Italy 371
10.5.1 Forecast 371
10.5.2 Key Events 376
10.5.3 Drivers and Barriers 376
10.6 Spain 378
10.6.1 Forecast 378
10.6.2 Key Events 384
10.6.3 Drivers and Barriers 385
10.7 United Kingdom 387
10.7.1 Forecast 387
10.7.2 Key Events 393
10.7.3 Drivers and Barriers 393
10.8 Japan 396
10.8.1 Forecast 396
10.8.2 Key Events 401
10.8.3 Drivers and Barriers 401
10.9 Australia 404
10.9.1 Forecast 404
10.9.2 Key Events 409
10.9.3 10.9.3 Drivers and Barriers 409
10.10 China 411
10.10.1 Forecast 411
10.10.2 Key Events 416
10.10.3 Drivers and Barriers 416
10.11 India 418
10.11.1 Forecast 418
10.11.2 Key Events 423
10.11.3 Drivers and Barriers 423
11 Appendix 426
11.1 Bibliography 426
11.2 Abbreviations 452
11.3 Methodology 459
11.4 Forecasting Methodology 459
11.4.1 Diagnosed RA Patients 459
11.4.2 Percentage of Drug-Treated Patients 460
11.4.3 Drugs Included in Each Therapeutic Class 460
11.4.4 Launch and Patent Expiry Dates 461
11.4.5 General Pricing Assumptions 462
11.4.6 Individual Drug Assumptions 464
11.4.7 Generic and Biosimilar Erosion 476
11.4.8 Pricing of Pipeline Agents 476
11.5 Primary Research – KOLs Interviewed for This Report 479
11.6 Primary Research – Prescriber Survey 481
11.7 About the Authors 481
11.7.1 Analyst 481
11.7.2 Reviewer 482
11.7.3 Therapy Area Director 482
11.7.4 Epidemiologist 483
11.7.5 Global Head of Healthcare 484
11.8 About GlobalData 485
11.9 Disclaimer 485